http://musc.technologypublisher.comBe the first to know about the latest inventions and technologies available from Zucker Institute of Innovation Commercialization powered by MUSC en-USFri, 10 Apr 2026 07:58:09 GMTTue, 07 Feb 2023 05:43:44 GMThttp://blogs.law.harvard.edu/tech/rssziic@musc.eduCopyright 2026, MUSC Foundation for Research DevelopmentP22072http://musc.technologypublisher.com/technology/50317Tue, 07 Feb 2023 05:43:44 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/50317P1709http://musc.technologypublisher.com/technology/50316Tue, 07 Feb 2023 05:39:51 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/50316P1732http://musc.technologypublisher.com/technology/47690The global preclinical imaging market is estimated to reach 910 million in the US alone by 2021, including utilizing bioluminescent probes to study biological processes in vitro and in vivo in real time, image cancer cells, monitor gene delivery and adoptively transferred cells and track pathogen clearance, detect apoptosis and research signal transduction. Current limitations with many bioluminescence probes are the need for an external light source to excite the probe. Lucerifase based probes overcome this issue, however, D-luciferin or other small molecule substrates only last a very short ...Fri, 15 Jul 2022 14:27:11 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/47690P14108http://musc.technologypublisher.com/technology/47689Technology: Progenitor cells provide strong regenerative ability, but are limited by their immature phenotype and inability to generate functional tissues equivalent to adult cardiomyocytes. This technology provides a novel approach to successfully regenerate functional cardiomyocytes from progenitor cells. The strategy involves providing a physiologically-relevant microenvironment to develop immature stem cells into functional mature cardiomyocytes by incorporating electrically conductive nanowires (e-NWs) into a scaffold-free, progenitor cell construct that are intrinsically compatible with ...Fri, 15 Jul 2022 13:46:05 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/47689P1348http://musc.technologypublisher.com/technology/47687Researchers at MUSC have developed a rapid and reproducible method for the cryopreservation of a variety of tissues, such that when thawed are comparable to freshly resected tissues. To date, analysis has been completed on lung tissue from patients undergoing lobectomy or transplant and prostate tissue. This method involves the pseudo-diaphragmatic expansion (rapid and thorough perfusion) of pieces of freshly resected tissue utilizing a universal cryoprotectant (PDX-CP) followed by controlled-rate freezing in cryovials. Expansion-perfusion rates, volumes and the cryoprotectant formulation have...Fri, 15 Jul 2022 10:12:34 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/47687P14105http://musc.technologypublisher.com/technology/45448Sun, 28 Nov 2021 14:12:48 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/45448P1672http://musc.technologypublisher.com/technology/44889Thu, 09 Sep 2021 07:32:58 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/44889P20144http://musc.technologypublisher.com/technology/43815 Technology: Inventors at MUSC have identified that NAc (nucleus accumbens) G9a is required for stress-regulated drinking in both ethanol-dependent and non-dependent animals. Importantly they discovered that treating mice with UNC0642 (an inhibitor of G9a) in a stressinduced ethanol drinking assay (Figure. 1A) showed significant reduction in ethanol consumption during first week of daily drug injections (Figure. 1B). Further, chronic UNC0642 treatment suppressed U50,488 (kappa opiod agonist) potentiated ethanol drinking observed in control mice (Figure. 1C). Current treatment modalities ...Thu, 03 Jun 2021 10:14:16 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/43815P20031http://musc.technologypublisher.com/technology/43507Wed, 05 May 2021 10:06:35 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/43507P19125http://musc.technologypublisher.com/technology/43295Fri, 26 Mar 2021 09:41:04 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/43295P20043http://musc.technologypublisher.com/technology/43028 Technology: Inventors at MUSC have designed fusion proteins to treat inflammatory and other related pathologies by binding p-selectin (PSel) and modulating complement. Although targeting complement has shown great promise in treating numerous pathologies which has also led to the approval of multiple drugs (e.g. eculizumab, Berinert, Cinryze), targeting PSel offers a more targeted approach over complement because PSel is specifically expressed at sites of inflammation. For example, C3, the CR2 target, is expressed in healthy kidneys, spleen and lymph nodes, and on pathogens as a clearance mec...Tue, 16 Feb 2021 06:20:10 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/43028P20111http://musc.technologypublisher.com/technology/42806Thu, 28 Jan 2021 05:46:04 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/42806P19116http://musc.technologypublisher.com/technology/42145 Technology: Surgeons and researchers at MUSC have created a non-invasive, motion-activated, closed-loop vagus nerve simulation (VNS) device that enhances neuroplasticity to accelerate motor restoration in post-stroke rehabilitation. The device couples VNS with limb motion to provide stimulation simultaneously with movement, enhancing the effects of post-stroke rehabilitation. As an example, when the arm is targeted, different muscle groups in the arm can be monitored by EMG electrodes. Limb movement can be initiated by the patient independently or can be guided by a robotic or therapist. Once...Thu, 22 Oct 2020 07:24:32 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/42145P20075http://musc.technologypublisher.com/technology/42110Technology: Researchers at MUSC have identified methods for selectively modifying linked sialic acid or polysialic acid with bioorthagonal reaction schemes having applications broad applications in drug delivery. This is achieved by exposing a 2,3 linked sialic acid and/or a 2,8 linked polysialic acid to condensing reagents under suitable reaction conditions. The selectively modified sialic acid can be paired with a payload molecule (molecule used to deliver an active agent) to induce a biological or physiological effect to the subject. The payload molecule can range from a pharmaceutical drug...Mon, 19 Oct 2020 05:26:16 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/42110P1111http://musc.technologypublisher.com/technology/39150Thu, 12 Mar 2020 07:23:29 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/39150P1791http://musc.technologypublisher.com/technology/36347Mon, 23 Sep 2019 05:15:50 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/36347P1915http://musc.technologypublisher.com/technology/36334Thu, 19 Sep 2019 06:09:39 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/36334P1810http://musc.technologypublisher.com/technology/35523 Technology: MUSC researchers have developed a novel therapy to treat sepsis and Acute Respiratory Distress Syndrome (ARDS) using endothelial progenitor cell-derived (EPC) exosomes, which reduced lung and organ injury, inflammation response, and increased survival rate in a mouse model. Data gathered showed that in a sepsis model, IV administration of EPC exosomes significantly increased the survival rate of Cecal Lingation Puncture (CLP)-induced sepsis mice compared to placebo and non-EPC exosome groups (figure 1). CLP-induced sepsis mice also had a significant cytokine and chemokine reduc...Tue, 20 Aug 2019 05:45:14 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/35523P1872http://musc.technologypublisher.com/technology/35405Tue, 13 Aug 2019 05:43:44 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/35405P1951http://musc.technologypublisher.com/technology/34375Technology: Surgeons and researchers at MUSC have created a new design for a skin hook that enables a gripping orientation more clinician-friendly from the traditional pencil-grip style. The design terminates in a loop that may fit around a finger. This loop design may reduce fatigue and permit a single hand to hold more than one skin hook. While introducing this new gripping method, the design also allows a traditional pencil-grip holding technique if desired. Overview: This design would be useful in any procedure where skin hooks are necessary, particularly procedures that are long or req...Wed, 22 May 2019 06:06:45 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/34375P1938http://musc.technologypublisher.com/technology/31775Technology: Inventors from MUSC have identified a class of brominated alkaloid compounds, including aleutianamine, which has potent bioactivity across multiple cancer cell lines in vitro. Extraction and purification of specimens of Latrunculia austini, led to isolation of a potential target mass m/z 398 that resulted from MS/MS molecular ion networking-MoIN analysis (vide supra) as a green-yellow solid with the molecular formula of C18H13BrN3OS generated by high-resolution mass spectrometry analysis (Figure 1). Aleutianamine, with its unique ring system, showed anti-cancer selectivity in a dif...Mon, 18 Mar 2019 07:41:25 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/31775P0847http://musc.technologypublisher.com/technology/31592Fri, 01 Mar 2019 12:31:21 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/31592P1705http://musc.technologypublisher.com/technology/28658Thu, 06 Sep 2018 05:29:08 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/28658P1840http://musc.technologypublisher.com/technology/28504Thu, 16 Aug 2018 10:14:26 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/28504P1863http://musc.technologypublisher.com/technology/27710Wed, 16 May 2018 10:45:51 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/27710P1790http://musc.technologypublisher.com/technology/27390Mon, 19 Mar 2018 08:20:53 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/27390P1788http://musc.technologypublisher.com/technology/26820Thu, 04 Jan 2018 14:32:24 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/26820P1410ahttp://musc.technologypublisher.com/technology/26229Wed, 13 Sep 2017 08:24:46 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/26229P1755http://musc.technologypublisher.com/technology/26069Tue, 22 Aug 2017 05:13:30 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/26069P1641http://musc.technologypublisher.com/technology/25496 Technology: Currently, there are only two approved therapies for Idiopathic Pulmonary Fibrosis (IPF), pirfenidone and nintedanib, which are minimally effective at slowing the disease. These treatments are not effective at all in halting or reversing the progression of IPF. Therefore, there remains a great need for more effective therapies. Researchers at MUSC and Pittsburgh have found that a novel compound, MMS-350, can significantly reduce pro-fibrotic factors and ECM proteins both in vitro and in vivo. Figure 1 demonstrates that in bleomycin treated mice oral doses of MMS-350 ameliorates fi...Wed, 14 Jun 2017 13:07:25 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/25496P1412ahttp://musc.technologypublisher.com/technology/25012Tue, 04 Apr 2017 04:58:58 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/25012P1531http://musc.technologypublisher.com/technology/22547Tue, 26 Jul 2016 14:39:07 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/22547P1332http://musc.technologypublisher.com/technology/22438Wed, 13 Jul 2016 08:23:07 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/22438P1605http://musc.technologypublisher.com/technology/20388Clinical experts at the Medical University of South Carolina have created protocols as guidelines for treatment by telehealth providers. This telehealth model will require high-definition video conferencing and a suite of diagnostic instruments that provide real-time data to the telehealth provider. These instruments include a digital otoscope and stethoscope. To practice in this telehealth model, providers and telepresenters must meet qualifications established by MUSC. Providers practicing in this model will also be required to participate in a continuing quality assurance program developed ...Thu, 24 Sep 2015 10:07:08 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/20388P1143http://musc.technologypublisher.com/technology/20237Tue, 08 Sep 2015 09:33:03 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/20237P1454http://musc.technologypublisher.com/technology/20152 Technology: Treatment with peptide (M10) derived from mesenchymal epithelial transition factor (c-MET) demonstrates antifibrotic properties in systemic sclerosis. M10 is a ten-amino acid peptide (TRPASFWETS) derived from intracellular cytoplasmic tail of MET upon cleavage by caspase-3 enzyme. Aspartic acid residue at position 1398 of MET is essential for M10 generation. In lung fibroblasts, A549 lung cancer cells and alveolar epithelial cells expressing the D1398G variant of MET exhibit reduced auto-phosphorylation on tyrosine residues and reduced activation of Ras and MAPK, which results in ...Tue, 25 Aug 2015 11:03:12 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/20152P14103http://musc.technologypublisher.com/technology/19700Tue, 02 Jun 2015 09:30:31 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/19700P1504http://musc.technologypublisher.com/technology/18710Tue, 24 Mar 2015 09:01:10 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18710Software Technologhttp://musc.technologypublisher.com/technology/18281Sat, 14 Feb 2015 14:38:15 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18281Imaging Algorithmshttp://musc.technologypublisher.com/technology/18280Sat, 14 Feb 2015 14:17:01 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18280Medical Deviceshttp://musc.technologypublisher.com/technology/18279Sat, 14 Feb 2015 14:05:42 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18279Diagnostic Technolohttp://musc.technologypublisher.com/technology/18277Sat, 14 Feb 2015 13:41:12 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18277Other Therapeuticshttp://musc.technologypublisher.com/technology/18272Fri, 13 Feb 2015 10:18:30 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18272Neurology Therapeutihttp://musc.technologypublisher.com/technology/18271MUSC Neurology Therapeutics: Therapeutics for Epilepsy and other Neurological Disordershttp://musc.technologypublisher.com/technology/12246 Compounds for Induction of Mitochondrial Biogenesishttp://musc.technologypublisher.com/technology/12247 Nucleosides Analogs for Cardiovascular and Neurodegenerative Diseaseshttp://musc.technologypublisher.com/technology/10162Fri, 13 Feb 2015 10:05:24 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18271Oncology Therapeutichttp://musc.technologypublisher.com/technology/18270MUSC Oncology Therapeutics: Liposomal Delivery of Encapsulated Therapeutics to Treat Pediatric Brain Tumorshttp://musc.technologypublisher.com/technology/17463 LSD1 Protein Inhibitors as Epigenetic Modulatorshttp://musc.technologypublisher.com/technology/15182 Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1 (LSD1)http://musc.technologypublisher.com/technology/15181 Chaperone-based Integrin Inhibitors for the Treatment of Cancer and Inflammatory Diseaseshttp://musc.technologypublisher.com/technology/13451 Antibody Therapeutic for EGFR-expressing Cancershttp://musc.technologypubl...Fri, 13 Feb 2015 10:05:23 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18270Fibrosis Therapeutichttp://musc.technologypublisher.com/technology/18255MUSC Fibrosis Therapeutics Anti-Fibrotic Peptidehttp://musc.technologypublisher.com/technology/15216 A Novel Composition for Wound Healing and Tissue Repairhttp://musc.technologypublisher.com/technology/9562 Peptide for Treatment and Reversal of Fibrosishttp://musc.technologypublisher.com/technology/18231 Cardiac Repair Therapyhttp://musc.technologypublisher.com/technology/6651 Mon, 09 Feb 2015 12:02:12 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/18255P1518http://musc.technologypublisher.com/technology/17788Inventors have developed a biofabrication platform that can be tuned to mimic the native in vivo architecture and geometries vital to the physiological function of tissue. The inventors use a new material for molding intrinsic geometries to an in vitro collagen hydrogel by allowing the adequate transfer of the specific architectural features to a natural scaffold material. The biofabrication platform utilizes state of the art imaging, micromachining, and selective enzymatic activity in order to achieve a new generation of biomaterials for research and clinical applications. The biomaterials ha...Wed, 07 Jan 2015 06:20:40 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/17788P1242http://musc.technologypublisher.com/technology/17411Wed, 22 Oct 2014 06:45:06 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/17411P1254http://musc.technologypublisher.com/technology/15236Tue, 20 May 2014 12:43:41 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/15236P1412http://musc.technologypublisher.com/technology/15182Technology: Researchers at MUSC have identified several potential inhibitors of lysine-specific demethylase 1 (LSD1) utilizing a virtual screen and found compounds that fit the LSD1 active site in silico. LSD1 is overexposed in a number of human cancers (neuroblastoma, retinoblastoma, prostate, cancer, lung, and bladder), and has emerged as an important target for the development of specific inhibitors as a new class of antitumor drugs. Researchers have synthesized these molecules and evaluated them as LSD1 inhibitors, and several compounds inhibit the enzyme with Ki values in the mid-to upper...Tue, 13 May 2014 06:20:04 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/15182P1410http://musc.technologypublisher.com/technology/15181Tue, 13 May 2014 06:19:47 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/15181P1440http://musc.technologypublisher.com/technology/14999Tue, 08 Apr 2014 11:00:56 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/14999P0730http://musc.technologypublisher.com/technology/9538Tue, 12 Jun 2012 15:11:06 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/9538P0923http://musc.technologypublisher.com/technology/7003Technology: The inventors have developed a methodology that has been robustly validated (~800 patients) to accurately and reliably measure Ox-LDL, AGE-LDL and other modified LDLs circulating in bound/immune-complex (IC) form. The method involves isolation of IC from blood samples and fractionation of the isolated IC in order to separate modified forms of LDL that can then be quantitated with specific antibodies to Ox-LDL, MDA-LDL and AGE-LDL. The concentrations and relative distribution of modified LDL contained in the IC have been identified as risk factors for the progression of coronary hea...Tue, 19 Apr 2011 07:17:30 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/7003P0804http://musc.technologypublisher.com/technology/6649Sun, 27 Mar 2011 10:51:25 GMTziic@musc.eduhttp://musc.technologypublisher.com/technology/6649